Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10029


Purpose:

To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.


Criteria:

Inclusion Criteria: - Present with chronic moderate-to-severe plaque psoriasis based on a confirmed (by a dermatologist) diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline - Active psoriatic skin lesions of plaque psoriasis (Ps) - Are a candidate for phototherapy and/or systemic therapy - Men must agree to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment - Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment Exclusion Criteria: - Are unable to commit to the photography schedule for the duration of the study - Have participated in any study with interleukin 17 (IL-17) or (IL-23) antagonists, including ixekizumab - Serious disorder or illness other than psoriasis - Serious infection within the last 3 months - Breastfeeding or nursing (lactating) women


NCT ID:

NCT02387801


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company


Backup Contact:

N/A


Location Contact:

New York, New York 10029
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.